Immunic secures $400 million fund to support commercial-stage development
Immunic has announced an oversubscribed private placement of up to $400 million, strengthening its move from an R&D-focused organization to a commercial-stage entity. The placement was led by existing investor BVF Partners and was joined by entities such as Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital and other institutional investors. The company…